Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19

Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection causes coronavirus disease-2019 (COVID-19) in some individuals, while the majority remain asymptomatic. Natural killer (NK) cells play an essential role in antiviral defense. NK cell maturation and function are regulated mainly by highly polymorphic killer cell immunoglobulin-like receptors (KIR) and cognate HLA class I ligands. Herein, we tested our hypothesis that the individualized KIR and HLA class I ligand combinations that control NK cell function determine the outcome of SARS-CoV-2 infection. Methods: We characterized KIR and HLA genes in 200 patients hospitalized for COVID-19 and 195 healthy general population controls. Results: The KIR3DL1+HLA-Bw4+ [Odds ratio (OR) = 0.65, p = 0.03] and KIR3DL2+HLA-A3/11+ (OR = 0.6, p = 0.02) combinations were encountered at significantly lower frequency in COVID-19 patients than in the controls. Notably, 40% of the patients lacked both of these KIR+HLA+ combinations compared to 24.6% of the controls (OR = 2.04, p = 0.001). Additionally, activating receptors KIR2DS1+KIR2DS5+ are more frequent in patients with severe COVID-19 than patients with mild disease (OR = 1.8, p = 0.05). Individuals carrying KIR2DS1+KIR2DS5+ genes but missing either KIR3DL1+HLA-Bw4+ combination (OR = 1.73, p = 0.04) or KIR3DL2+HLA-A3/11+ combination (OR = 1.75, p = 0.02) or both KIR3DL1+HLA-Bw4+ and KIR2DL2+HLA-A3/11+ combinations (OR = 1.63, p = 0.03) were more frequent in the COVID-19 cohort compared to controls. Conclusions: The absence of KIR3DL1+HLA-Bw4+ and KIR3DL2+HLA-A3/11+ combinations presumably yields inadequate NK cell maturation and reduces anti-SARS-CoV-2 defense, causing COVID-19. An increased frequency of KIR2DS1+KIR2DS5+ in severe COVID-19 patients suggests vigorous NK cell response triggered via these activating receptors and subsequent production of exuberant inflammatory cytokines responsible for severe COVID-19. Our results demonstrate that specific KIR-HLA combinations that control NK cell maturation and function are underlying immunogenetic variables that determine the dual role of NK cells in mediating beneficial antiviral and detrimental pathologic action. These findings offer a framework for developing potential host genetic biomarkers to distinguish individuals prone to COVID-19.

[1]  A. Hajeer,et al.  Association of KIR gene polymorphisms with COVID-19 disease , 2021, Clinical Immunology.

[2]  G. Cınar,et al.  A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity , 2021, Immunogenetics.

[3]  S. Stilgenbauer,et al.  Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019 , 2021, Intensive Care Medicine Experimental.

[4]  M. Chiron,et al.  Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma , 2021, Journal for ImmunoTherapy of Cancer.

[5]  Panteleimon G. Takis,et al.  Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study , 2021, The Lancet.

[6]  H. Ljunggren,et al.  Natural killer cells in antiviral immunity , 2021, Nature reviews. Immunology.

[7]  R. Rajalingam,et al.  Concurrent typing of over 4000 samples by long-range PCR amplicon-based NGS and rSSO revealed the need to verify NGS typing for HLA allelic dropouts. , 2021, Human immunology.

[8]  M. Mckay,et al.  Activating Killer-cell Immunoglobulin-like Receptors are associated with the severity of COVID-19 , 2021, The Journal of infectious diseases.

[9]  A. Ghaderi,et al.  Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk , 2021, Scientific Reports.

[10]  P. Pelosi,et al.  Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity , 2021, PLoS pathogens.

[11]  C. Yiannoutsos,et al.  How Many SARS-CoV-2–Infected People Require Hospitalization? Using Random Sample Testing to Better Inform Preparedness Efforts , 2021, Journal of public health management and practice : JPHMP.

[12]  G. Deniz,et al.  The Role of Natural Killer Cells in Autoimmune Diseases , 2021, Frontiers in Immunology.

[13]  Xiandong Tao,et al.  Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients , 2021, Experimental Hematology & Oncology.

[14]  Martínez-Sánchez.  Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019 , 2021 .

[15]  F. Meloni,et al.  Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. , 2021, PloS one.

[16]  J. C. Cohen Tervaert,et al.  Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19 , 2020, Blood Advances.

[17]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[18]  B. Reinius,et al.  Natural killer cell immunotypes related to COVID-19 disease severity , 2020, Science Immunology.

[19]  C. Agrati,et al.  Immunological and inflammatory profiles in mild and severe cases of COVID-19 , 2020, Nature Communications.

[20]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[21]  Raj Bhopal,et al.  Sharpening the global focus on ethnicity and race in the time of COVID-19 , 2020, The Lancet.

[22]  Jie Dong,et al.  Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients , 2020, Cell Host & Microbe.

[23]  Zhiyong Ma,et al.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.

[24]  Z. Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[25]  A. Hajeer,et al.  Common, intermediate and well‐documented HLA alleles in world populations: CIWD version 3.0.0 , 2020, HLA.

[26]  R. Rajalingam.  Diversity of Killer Cell Immunoglobulin-Like Receptors and Disease. , 2018, Clinics in laboratory medicine.

[27]  R. Rajalingam,et al.  Inhibitory natural killer cell receptor KIR3DL1 with its ligand Bw4 constraints HIV-1 disease among South Indians , 2018, AIDS.

[28]  T. Kepler,et al.  The Egyptian Rousette Genome Reveals Unexpected Features of Bat Antiviral Immunity , 2018, Cell.

[29]  P. Parham,et al.  KIR2DS5 allotypes that recognize the C2 epitope of HLA‐C are common among Africans and absent from Europeans , 2017, Immunity, inflammation and disease.

[30]  L. Moretta,et al.  KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing , 2017, Front. Immunol..

[31]  J. Rossjohn,et al.  Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1 , 2015, Journal of Virology.

[32]  E. Ren,et al.  Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11 , 2014, Proceedings of the National Academy of Sciences.

[33]  K. Hsu,et al.  KIR3DL1 and HLA-Bw4 Allotypes Predict The Extent Of NK Cell Licensing , 2013 .

[34]  M. Carrington,et al.  Immunogenetics of HIV disease , 2013, Immunological reviews.

[35]  J. Chewning,et al.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. , 2012, The New England journal of medicine.

[36]  P. Parham,et al.  Mutation at Positively Selected Positions in the Binding Site for HLA-C Shows That KIR2DL1 Is a More Refined but Less Adaptable NK Cell Receptor Than KIR2DL3 , 2012, The Journal of Immunology.

[37]  F. Plummer,et al.  Enrichment of Variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU Patients: An Exploratory Study , 2011, PloS one.

[38]  M. Hayley,et al.  Self-Association of an Activating Natural Killer Cell Receptor, KIR2DS1 , 2011, PloS one.

[39]  E. Romeo,et al.  Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. , 2011, Blood.

[40]  M. Parsons,et al.  Killer cell immunoglobulin‐like receptor 3DL1 licenses CD16‐mediated effector functions of natural killer cells , 2010, Journal of leukocyte biology.

[41]  E. Reed,et al.  KIR gene content diversity in four Iranian populations , 2009, Immunogenetics.

[42]  Joseph C. Sun,et al.  Tolerance of NK cells encountering their viral ligand during development , 2008, The Journal of experimental medicine.

[43]  E. Romeo,et al.  Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function , 2008, European journal of immunology.

[44]  F. Christiansen,et al.  KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. , 2008, International immunology.

[45]  É. Vivier,et al.  Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. , 2008, Blood.

[46]  R. Pitchappan,et al.  Distinct diversity of KIR genes in three southern Indian populations: comparison with world populations revealed a link between KIR gene content and pre-historic human migrations , 2008, Immunogenetics.

[47]  J. Piccirillo,et al.  HLA alleles determine differences in human natural killer cell responsiveness and potency , 2008, Proceedings of the National Academy of Sciences.

[48]  J. Chewning,et al.  KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro1 , 2007, The Journal of Immunology.

[49]  Mary Carrington,et al.  KIR and disease: a model system or system of models? , 2006, Immunological reviews.

[50]  D. Gjertson,et al.  Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans , 2006, Immunogenetics.

[51]  M. Carrington,et al.  The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. , 2006, Annual review of genomics and human genetics.

[52]  D. Middleton,et al.  Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.

[53]  Eric Vivier,et al.  Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Andrew Glass,et al.  Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci , 2005 .

[55]  Sumati Rajagopalan,et al.  Understanding how combinations of HLA and KIR genes influence disease , 2005, The Journal of experimental medicine.

[56]  P. Parham.  MHC class I molecules and kirs in human history, health and survival , 2005, Nature Reviews Immunology.

[57]  S. Rowland-Jones,et al.  Recognition of HLA‐A3 and HLA‐A11 by KIR3DL2 is peptide‐specific , 2004, European journal of immunology.

[58]  Mitchell Kronenberg,et al.  Constitutive Cytokine mRNAs Mark Natural Killer (NK) and NK T Cells Poised for Rapid Effector Function , 2003, The Journal of experimental medicine.

[59]  X. Saulquin,et al.  Crystal Structure of the Human Natural Killer Cell Activating Receptor KIR2DS2 (CD158j) , 2003, The Journal of experimental medicine.

[60]  X. Saulquin,et al.  Crystal Structure of the Human Natural Killer Cell Activating Receptor KIR 2 DS 2 ( CD 158 j ) , 2003 .

[61]  K. Cao,et al.  Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. , 2001, Human immunology.

[62]  C. Biron,et al.  Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.

[63]  Eric O Long,et al.  Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. , 1998, Journal of immunology.

[64]  L. Lanier.  NK cell receptors. , 1998, Annual review of immunology.

[65]  R. Biassoni,et al.  Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA‐Cw4 molecules , 1997, European journal of immunology.

[66]  M. Colonna,et al.  A human killer inhibitory receptor specific for HLA-A1,2. , 1996, Journal of immunology.

[67]  L. Moretta,et al.  Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells , 1995, The Journal of experimental medicine.

[68]  P. Parham,et al.  The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor , 1995, The Journal of experimental medicine.

[69]  J L Sullivan,et al.  Severe herpesvirus infections in an adolescent without natural killer cells. , 1989, The New England journal of medicine.

[70]  I. Kimber.  Natural killer cells. , 1985, Medical laboratory sciences.